Short answer
Syndax Pharmaceuticals Inc (SNDX) filed its Q1 2026 10-Q quarterly report on Apr 30, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $65M (up 223.6% year over year) with net income of −$43M.
Q1 2026 key financials · XBRL
- Revenue
- $65M
- +223.6% YoY
- Net income
- −$43M
- +49.7% YoY
- Operating margin
- -52.7%
- EPS (diluted)
- −$0.48
- +51.0% YoY
Source: XBRL data from the Syndax Pharmaceuticals Inc (SNDX) Q1 2026 10-Q on SEC EDGAR. USD.
Syndax Pharmaceuticals Inc Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- Executive and director Rule 10b5-1 plans adopted for 255,890 shares during March 2026
- CEO Michael A. Metzger plan covers 182,375 shares, expiring December 15, 2027
- Head of R&D Nicholas Botwood plan covers 65,515 shares, expiring October 30, 2026
- Director Dennis Podlesak plan disclosure corrected after omission from December 31, 2025 filing
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Syndax Pharmaceuticals Inc quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.